{
    "pmcid": "11140877",
    "qa_pairs": {
        "How can nanobodies be engineered to enhance their neutralizing potency and avidity?": [
            "By creating multivalent formats such as bivalent or trivalent nanobodies",
            "By increasing their molecular weight",
            "By reducing their binding affinity",
            "By shortening their CDR3 region"
        ],
        "What characteristic of nanobodies allows them to access epitopes difficult for conventional antibodies to reach?": [
            "Their long complementarity-determining region 3 (CDR3)",
            "Their ability to form multivalent formats",
            "Their fusion with Fc regions",
            "Their larger size compared to conventional antibodies"
        ],
        "What is a potential advantage of nanobodies targeting conserved RBD epitopes?": [
            "They may retain efficacy against multiple variants.",
            "They are more likely to lose effectiveness against new variants.",
            "They are less stable under extreme conditions.",
            "They have a shorter half-life in the bloodstream."
        ],
        "What is the primary function of the SARS-CoV-2 spike protein's S1 subunit?": [
            "It contains the receptor-binding domain (RBD) and the N-terminal domain (NTD) for viral entry.",
            "It facilitates membrane fusion with host cells.",
            "It provides structural support to the viral envelope.",
            "It is responsible for the replication of viral RNA."
        ],
        "Which mutations in the SARS-CoV-2 RBD are mentioned as critical for altering interaction with ACE2?": [
            "S477N, E484K, and N501Y",
            "D614G, P681R, and L452R",
            "H69/V70 deletion, Y144 deletion, and K417N",
            "T478K, Q493R, and G446S"
        ]
    }
}